GSK Ends Tough Week With Ulcerative Colitis Therapy Termination
Big Blow For Partner Immutep
If bad luck comes in threes, GSK will be delighted to see the end of this week with dostarlimab approval delayed, bintrafusp failing in lung cancer and a Phase II of an ulcerative colitis drug discontinued.
